Abstract： Objective To study the anticoagulant effect of and bleeding events with small-dose argatroban injection in continuous renal placement therapy (CRRT). Methods Sixty-seven patients undergoing continuous renal replacement therapy were continuously given gargatroban injection at the initial dose of 0.1 μg/kg, and then 0.05 μg/(kg·min), by a micro pump from the origin of the artery. Patients' anticoagulant function was examined, and coagulation, bleeding and hematoma around punctures were evaluated before and 1 h after treatment and 2 h after treatment, as well as every 2 h during treatment. Results There was no significant difference in coagulation before and after treatment, and no significant bleeding and hematoma were found around punctures. There was significant difference in the activaved partial thromboplastin time (APPT) and prothrombin time (PT) before and 1 h after treatment (P<0.05). No difference was found before and 2 h after treatment. The PT and APTT of the artery and vein examined 1 h after treatment showed significant difference (P<0.05). Conclusions A small dose of argatroban achieves anticoagulant effect and causes no bleeding events. So the anticoagulant effect of using small-dose argatroban is safe and reliable in continuous renal replacement therapy.
2012, Vol. 23 
